What disease does Zynlonta treat?

Tarantuximab (Zynlonta) is a drug used to treat a malignant blood cancer called "diffuse large Bcell lymphoma" (DLBCL). DLBCL is a common but aggressive subtype of non-Hodgkin lymphoma that originates primarily from B cells in lymphoid tissue and is often characterized by rapid growth and spread. This form of cancer can appear in multiple parts of the body, including lymph nodes, spleen, bone marrow and other tissues.

Tarantuximab is a new type of targeted therapy designed to help patients with DLBCL who have received multiple treatments but are still not effectively controlled. Here is some key information about tarantuximab:

The core mechanism of tarantuximab involves targeting of the CD19 antigen. CD19 is a protein that exists on the surface of B cells, and DLBCL mainly originates from B cells. The drug consists of a special antibody that precisely recognizes and binds to CD19. Once tarentuximab binds to CD19 on the surface of DLBCL cells, it releases toxins that destroy these cancer cells, thereby inhibiting the progression of the disease.

Tarantuximab is approved for the treatment of adult patients with DLBCL, particularly those who have not achieved an effective response or have relapsed disease after at least two other lines of therapy. It is generally considered a "last resort treatment option" for those with more severe disease.

Tarantuximab's approval was based on the results of clinical trials that showed the drug had significant therapeutic benefits in some patients withDLBCL. United StatesFDATairantuximab was approved for marketing in April 2021, which marks that it has become an innovative treatment method that can be used by doctors to treat DLBCL.

The use of tarentuximab may cause a range of side effects, including fever, nausea, vomiting, fatigue, anemia, and an increased risk of infection. Due to its mechanism, this drug may also cause some unpleasant symptoms related to cell breakdown, such as hemolytic anemia.